Evidence map›Paper›PMID 35804982›Full record

ArticleCancers2022

Tensin2 Is a Novel Diagnostic Marker in GIST, Associated with Gastric Location and Non-Metastatic Tumors.

Sami Salmikangas, Tom Böhling, Nanna Merikoski, Joanna Jagdeo, Mika Sampo, Tiina Vesterinen, Harri Sihto

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Pharmacokinetic profile andDrug delivery · 2025
    Article
  3. Phosphodiesterase 3 A expression in gastrointestinal stromal tumors.Virchows Archiv : an international journal of pathology · 2025
    Article
  4. Review
  5. Cancers · 2023
    Article
  6. Article
  7. The molecular and clinical role of Tensin 1/2/3 in cancer.Journal of cellular and molecular medicine · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sami SalmikangasDepartment of Pathology, University of Helsinki and Helsinki University Hospital, FI-00014 Helsinki, Finland.ORCID 0000-0002-6264-4587
Tom BöhlingDepartment of Pathology, University of Helsinki and Helsinki University Hospital, FI-00014 Helsinki, Finland.ORCID 0000-0001-8903-3690
Nanna MerikoskiDepartment of Pathology, University of Helsinki and Helsinki University Hospital, FI-00014 Helsinki, Finland.
Joanna JagdeoDepartment of Pathology, University of Helsinki and Helsinki University Hospital, FI-00014 Helsinki, Finland.ORCID 0000-0001-7599-8395
Mika SampoDepartment of Pathology, HUSLAB, HUS Diagnostic Center, University of Helsinki and Helsinki University Hospital, FI-00029 Helsinki, Finland.
Tiina VesterinenDepartment of Pathology, HUSLAB, HUS Diagnostic Center, University of Helsinki and Helsinki University Hospital, FI-00029 Helsinki, Finland.ORCID 0000-0003-2997-0337
Harri SihtoDepartment of Pathology, University of Helsinki and Helsinki University Hospital, FI-00014 Helsinki, Finland.ORCID 0000-0001-5265-5509
University of Helsinki · FI

Funding

Cancer Foundation FinlandHelsinki University Hospital research fundJane and Aatos Erkko Foundation 4706174Medicinska Understödsföreningen Liv och HälsaUniversity of Helsinki 7360411University of Helsinki 73712712
6 · The paper itself

Abstract

GIST is a rare soft tissue sarcoma, for which KIT and DOG1 are used as highly sensitive diagnostic markers. Other diagnostic markers include CD34, protein kinase C θ, deficiency of succinate dehydrogenase complex subunit B, carbonic anhydrase II, and type I insulin-like growth factor receptor. We investigated the role of TNS2 as a diagnostic biomarker by using immunohistochemistry in 176 GISTs and 521 other sarcomas. All GISTs expressed TNS2, with intermediate or high expression in 71.4% of samples. The majority (89.8%) of other sarcomas were negative for TNS2, and intermediate to strong staining was only seen in 2.9% of samples. Strong TNS2 staining was associated with gastric location (gastric 52.8% vs. non-gastric 7.2%; p < 0.001), absence of metastases (non-metastatic tumors 44.3% vs. metastatic tumors 5.9%; p = 0.004), female sex (female 45.9% vs. male 33.8%; p = 0.029), and tumors of lower risk categories (very low or low 46.9% vs. intermediate 51.7% vs. high 29.0%; p = 0.020). TNS2 expression did not correlate with overall survival or metastasis-free survival. No associations between TNS2 expression and KIT/PDGFRA mutation status, tumor size, mitotic count, or age of the patient were detected. The results provide conclusive evidence for the value of TNS2 as a sensitive and specific diagnostic biomarker for GIST.

Indexed as

biomarkerdiagnostic markergastrointestinal stromal tumorGISTimmunohistochemistrysarcomaTensin2

Identifiers

PMID35804982
PMCPMC9265085
OpenAlexW4283759927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.